SC
CLDX icon

SummitTX Capital’s Celldex Therapeutics CLDX Stock Holding History

SummitTX Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.49M Buy
254,959
+18,322
+8% +$592K 0.24% 95
2026
Q1 		$7.51M Buy
236,637
+193,313
+446% +$5.27M 0.23% 99
2025
Q4 		$1.18M Sell
43,324
-52,746
-55% -$1.39M 0.04% 387
2025
Q3 		$2.49M Hold
96,070
– – 0.1% 213
2025
Q2 		$1.96M Buy
96,070
+10,000
+12% +$195K 0.08% 254
2025
Q1 		$1.56M Buy
+86,070
New +$1.92M 0.07% 298

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital's CLDX Position: Q2 2026 in Review

SummitTX Capital increased its Celldex Therapeutics (CLDX) stake by 7.7% in Q2 2026, buying an estimated $592K and bringing the position to 254,959 shares worth $9.49M. The position accounts for 0.24% of the portfolio, ranked #95.

SummitTX Capital first reported a position in CLDX in Q1 2025 and has held it in 6 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • SummitTX Capital held 254,959 shares of Celldex Therapeutics worth $9.49M as of Q2 2026.
  • SummitTX Capital bought 18,322 Celldex Therapeutics shares in Q2 2026, an estimated $592K.
  • Celldex Therapeutics made up 0.24% of SummitTX Capital's portfolio in Q2 2026, its #95 holding.
  • SummitTX Capital first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.